PubMed Health⌕ Search

PubMed · 2688235

[Hodgkin's disease--a histologic problem].

Abstract

Since the Rye classification of Hodgkin's disease, many lesions which resemble Hodgkin's disease microscopically have been described. The histological features of Hodgkin's disease, including the BNLI subclassification of nodular sclerosis, and the lesions which resemble Hodgkin's disease microscopically such as reactive lymph node hyperplasias, some non-Hodgkin's B- and T-cell lymphomas are reviewed. Recent reclassifications of lymphomas originally diagnosed as Hodgkin's disease have indicated that the disease was overdiagnosed, before the description of these lesions and before the development of monoclonal antibodies.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A F Lauritzen, L Specht, N I Nissen, K Hou-Jensen. 1989-11-20. [Hodgkin's disease--a histologic problem].. https://pubmed.ncbi.nlm.nih.gov/2688235/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.

The transcription factor NF-kappaB is a tightly regulated positive mediator of T- and B-cell development, proliferation, and survival. The controlled activity of NF-kappaB is required for the coordination of physiologic immune responses. However, constitutive NF-kappaB activation can promote continuous lymphocyte proliferation and survival and has recently been recognized as a critical pathogenetic factor in lymphoma. Various molecular events lead to deregulation of NF-kappaB signaling in Hodgkin disease and a variety of T- and B-cell non-Hodgkin lymphomas either up-stream or downstream of the central IkappaB kinase. These alterations are prerequisites for lymphoma cell cycling and blockage of apoptosis. This review provides an overview of the NF-kappaB pathway and discusses the mechanisms of NF-kappaB deregulation in distinct lymphoma entities with defined aberrant pathways: Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), mucosa-associated lymphoid tissue (MALT) lymphoma, primary effusion lymphoma (PEL), and adult T-cell lymphoma/leukemia (ATL). In addition, we summarize recent data that validates the NF-kappaB signaling pathway as an attractive therapeutic target in T- and B-cell malignancies.

Hodgkin Disease↗